Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 9/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.52 |
| ▸ | HPGD | P15428 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | POLB | P06746 | 3/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL834562 | 0.92 | LMNA (0.57) | LMNAKDM4ESMN1; SMN2KMT2AMEN1 | |
| SCHEMBL833585 | 0.90 | KDM4E (0.61) | LMNAKDM4ESMN1; SMN2KMT2AMEN1 | |
| SCHEMBL9920137 | 0.75 | MAPT (0.59) | LMNAKDM4ESMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL9920141 | 0.73 | KDM4E (0.79) | LMNAKDM4ESMN1; SMN2KMT2AMEN1 | |
| SCHEMBL834704 | 0.70 | ALDH1A1 (0.65) | LMNAKDM4ESMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL27181163 | 0.70 | HTT (0.59) | LMNAKDM4ESMN1; SMN2KMT2AMEN1 | |
| SCHEMBL30926684 | 0.70 | HTT (0.59) | LMNAKDM4ESMN1; SMN2KMT2AMEN1 | |
| SCHEMBL13532189 | 0.69 | RAD52 (0.77) | LMNAKDM4ESMN1; SMN2KMT2AMEN1 | |
| SCHEMBL14075285 | 0.69 | RAD52 (0.76) | LMNAKDM4ESMN1; SMN2KMT2AMEN1 | |
| SCHEMBL16085566 | 0.67 | SMN1; SMN2 (0.84) | LMNAKDM4ESMN1; SMN2KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149673-A1 | INHIBITORS OF STORE OPERATED CALCIUM RELEASE | CALCIMEDICA, INC. (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149673-A1 | INHIBITORS OF STORE OPERATED CALCIUM RELEASE | ORAI1, SARAF, RYR2 | LMNA 1170/4885KDM4E 4123/4885SMN1; SMN2 608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.